Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value

$11.62+0.72 (+6.61%)

Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –

Fennec Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2013 it was -$1.93M.

Period	Period end	Value	Change
FY2013	Dec 31, 2013	-$1.93M	–
FY2012	Dec 31, 2012	-$3.62M	–
FY2011	Dec 31, 2011	-$3.44M	–

Parsed from the XBRL in Fennec Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on Nov 13, 2014
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing